Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
21. Oktober 2024 15:58 ET
|
Tevogen Bio Inc
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
17. Oktober 2024 09:32 ET
|
Tevogen Bio Inc
Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
Genius Group Board implements 10 Year Performance Plan for CEO to achieve $1 billion market capitalization
20. Oktober 2023 08:00 ET
|
Genius Group Limited
SINGAPORE, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces today that its...
Trupanion Pays Out One Billion Dollars in Veterinary Invoices
24. Februar 2020 12:00 ET
|
Trupanion
SEATTLE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Trupanion, a leader in medical insurance for cats and dogs, announced today that it has paid out $1 billion in veterinarian invoices. The $1 billion...